Replies to post #161695 on Avid Bioservices Inc (CDMO)

[exwannabe]

Does Ramucirumab fall under 1 of the Peregrine/Thorpe patents?

It's a VEGF anti-angio agent (like Avistin), clearly no patent infringement.

[Protector]

Probably not because otherwise they would have announced the results which by lack of any indication other then 'statistical significant' point to be on the very poor side.

Not different from most other NSCLC trials with the exception of Bavi's 60% SOC improvement (and actually 101+% by what we know now about the dose switching).

Did they receive a FAST TRACK as did Bavi for 2nd ln NSCLC ?